Paracelsus Revisited: The Dose Concept in a Complex World by Grandjean, Philippe
Paracelsus Revisited: The Dose
Concept in a Complex World
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Grandjean, Philippe. 2016. “Paracelsus Revisited: The Dose Concept
in a Complex World.” Basic & Clinical Pharmacology & Toxicology
119 (2) (June 24): 126–132. Portico. doi:10.1111/bcpt.12622.
Published Version doi:10.1111/bcpt.12622
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34623032
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Open Access Policy Articles, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#OAP
Paracelsus Revisited: The Dose Concept in a Complex World
Philippe Grandjean
Department of Public Health, University of Southern Denmark, Odense, Denmark
Abstract
At the time that Paracelsus coined his famous dictum, “What is there that is not poison? All things 
are poison and nothing is without poison. Solely the dose determines that a thing is not a poison,” 
embryonic toxicology was a fairly focused discipline that mainly dealt with occupational 
poisonings and side effects of pharmaceuticals, such as mercury. While Paracelsus paved the way 
for the modern threshold concept and the no-adverse effect level, modern-day toxicology is now 
tussling with highly complex issues, such as developmental exposures, genetic predisposition and 
other sources of hypersusceptibility, multiple causes of underestimated toxicity, and the 
continuous presence of uncertainty, even in regard to otherwise well-studied mercury compounds. 
Further, the wealth of industrial chemicals now challenges the “untested-chemical assumption,” 
that the lack of documentation means that toxic potentials can be ignored. Unfortunately, in its 
ambition to provide solid evidence, toxicology has been pushed into almost endless replications, as 
evidenced by the thousands of toxicology publications every year that focus on toxic metals, 
including mercury, while less well-known hazards are ignored. From a public health viewpoint, 
toxicology needs to provide better guidance on decision-making under ever-present uncertainty. In 
this role, we need to learn from the stalwart Paracelsus the insistence on relying on facts rather 
than authority alone to protect against chemical hazards.
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A standard textbook on pharmacology notes: “Toxicology is often regarded as the science of 
poisons or poisoning, but developing a strict definition for poison is problematic”[1]. The 
reason for this paradox is that, in principle, any substance, including any drug or essential 
nutrient, has the capacity to harm a living organism and thus behave like a poison. The 
discovery of this conundrum is credited to the famous Renaissance physician Paracelsus 
(1493–1541), often referred to as the ”Father of Toxicology.” He was mainly writing in 
German, and a modern translation of his central dictum can be given as: “What is there that 
is not poison? All things are poison and nothing is without poison. Solely the dose 
determines that a thing is not a poison.” In this way, he paved the way for modern colleagues 
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to scrutinize the threshold concept and to define the no-adverse effect level (NOAEL) as the 
highest tested dose or concentration of a substance, at which no adverse effect is found. In 
fact, by defining that a (lower) dose will prevent adverse effects, Paracelsus laid the 
groundwork for the modern separation of the terms hazard and risk. I shall further discuss 
these issues below.
Many biographies on Paracelsus have been published, although much is unknown about him. 
Even his birth date is not at all certain, but sometime in late 1493, Philippus Theophrastus 
Aureolus Bombastus von Hohenheim was born. In the brief summary and the quotes that 
follow, I shall rely on a few excellent and easily accessible sources [2–8] and the most 
commonly used English translation [9].
Paracelsus was an academic name that he chose for himself, although he soon became 
known as a verdant critic of old masters like Galen and Hippocrates, and he infuriated his 
academic colleagues by burning the treasured classical textbooks. Further, he communicated 
in German, not in Latin, and refused to wear black robes. So his academic name should not 
be misinterpreted as a sign that he, like his contemporaries, based his thinking and teaching 
only on classic traditions and beliefs.
In fact, Paracelsus was not a particularly likable person. Though he was intelligent, well-
educated and deeply religious, he was also an unpredictable, stubborn, free-thinking and 
independent iconoclast. He gained a reputation for being arrogant and soon garnered the 
anger of other physicians when he demanded that they rely on facts and not on authority 
alone. As he said: “My accusers complain that I have not entered the temple of knowledge 
through the right door. But which one is the truly legitimate door - Galen and Avicenna, or 
Nature? I have entered through the door of Nature. Her light, not the lamp of an 
apothecary’s shop, has illuminated my way.”
He held a position at the University of Basel for less than a year and was forced from the 
city after a legal dispute over a physician’s fee he sued to collect. Paracelsus’ response 
highlights controversies that have reappeared many times since then: “The best of our 
popular physicians are the ones that do the least harm. But, unfortunately, some poison their 
patients with mercury; others purge them or bleed them to death. There are some who have 
learned so much that their learning has driven out all their common sense, and there are 
others who care a great deal more for their own profit than for the health of their patients.”
Paracelsus clearly made an impact, and he was aware that he looked peculiar (fig. 1) and 
acted peculiar: “I am different, let this not upset you.” But people did get upset by 
Paracelsus, and this is a main reason that he had difficulty getting his books published. In 
particular, the Carinthian Trilogy that included the first printed version of ”The Third 
Defense” – and his famous statement on poisons – was written in 1538 but was not 
published until 1564, more than 20 years after his death. Thus, it was only during the 
following decades, indeed, centuries, that the most visionary of his writings became 
appreciated.
After the skirmishes in Basel, Paracelsus wandered in Europe, Africa and Asia Minor in the 
pursuit of knowledge. Paracelsus may have reached Denmark, and it has been speculated 
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that he served as a military physician in Christian II’s army for as much as three years [10]. 
Paracelsus’ own wording does not provide much detail, though: ”Ich hab auch gesehen zu 
Stockhalma in Denmarck ein wunttrank bei einer edlen frauen” [10]. At the time, Christian 
II ruled and relied on the help of Mother Sigbrit (mother of the beautiful Dyveke) – was she 
the ”edle frau”? We can speculate – and I would like to believe that Paracelsus traveled 
through Odense, now almost 500 years ago.
Paracelsus is also famous for his clear description of the target organ concept and the 
occupational diseases in miners, among others. But his most famous clinical toxicology 
work was on mercury, which was applied as an important drug at the time, though limited by 
frequent side effects. I shall refer to mercury below, as it remains an important public health 
hazard, and compare it with a group of modern industrial chemicals now universally present 
in the environment and in ourselves, thereby complicating toxicology and Paracelsus’ dose 
concept.
 The elusive thresholds
Paracelsus’ ingenuity was his emphasis that lower doses – below a threshold – could cause 
otherwise poisonous substances to become harmless. While he recommended mercury (in 
the form of calomel and other inorganic mercury compounds) as a therapeutic in proper 
doses, side effects limited this application [11]. A widened perspective emerged when 
methylmercury, an organometal compound with a covalent bond between carbon and 
mercury, turned out to behave entirely differently and appeared to be even more toxic than 
elemental and inorganic mercury [12]. Further, the neurological signs of methylmercury 
poisoning in adults were unique [13]. This was particularly apparent during widespread 
poisoning incidents, which happened when seed grain treated with methylmercury as a 
fungicide was mistakenly used for bread-making. The most serious of these occurred during 
a famine in Iraq in 1970–1971 [14].
In the Japanese fishing village, Minamata, release of mercury-laden waste water from a local 
factory resulted in contamination of the fish, and an unusual clinical picture emerged among 
the local fishermen’s families in the 1950s. Most remarkably, apparently healthy women 
gave birth to children with a spastic paresis syndrome and mental retardation [15]. 
Recognition of the so-called Minamata disease as methylmercury poisoning was delayed, in 
part because thin-layer chromatography identification of the organometal compound was not 
possible until 1962 [16]. Soon, elevated methylmercury concentrations were documented in 
seafood, in tissues of deceased patients, and in umbilical cord samples from poisoned infants 
[17]. The discovery of the pervasive adverse effects on foetal development at dose levels that 
spared the mother supported a new paradigm later named Developmental Origins of Health 
and Disease (DOHaD) [18] – an important extension of Paracelsus’ teaching: “for exposures 
sustained during early development, another critical, but largely ignored, issue is that ‘the 
timing makes the poison’” [19].
Developmental vulnerability soon turned out to be only one of the reasons that susceptibility 
to a toxicant might vary. Genetic predisposition to toxic effects can render an individual 
highly vulnerable to particular toxicants [20]. When some individuals are much more 
Grandjean Page 3
Basic Clin Pharmacol Toxicol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
vulnerable to a toxicant like methylmercury, then the average effect, as documented in 
epidemiological studies, can be grossly misleading. For example, in a British birth cohort, 
the mercury concentration in cord tissue served as a marker also of maternal fish intake 
during pregnancy and showed no correlation with the children’s IQ at age 8 years. In 
contrast, among children with a genetic predisposition, each doubling of the methylmercury 
exposure was associated with a loss of as much as 6 IQ points [21]. Thus, we are not all 
equally sensitive to the risk of toxicity.
As a further complication, the exact dose absorbed by each environmentally exposed 
individual is often not known. Dietary questionnaires are inherently imprecise, and better 
data are usually obtained from determining the mercury concentrations in biological 
samples, such as blood or scalp hair [22]. Although these measurements can be affected by 
exposures to different forms of mercury, in seafood consumers they mainly reflect the 
methyl species. Laboratory analysis is normally associated with a relative imprecision better 
than 5% that can usually be ignored. However, several factors can influence the amount of 
mercury in the sample, whether external contamination, binding properties or temporal 
variability. Thus, for hair-mercury analyses, the total imprecision has been estimated to be 
about 50%, i.e., more than 10-fold greater than the analytical variability [23]. Unfortunately, 
this issue has not been widely appreciated, and a biomarker result, e.g., the hair-mercury 
concentration is generally assumed to represent an individual’s methylmercury exposure 
without error, thereby reflecting the amount that has reached the target organ. High 
imprecision levels cause misclassification of the exposure and thereby a bias toward the null 
[23]. Accordingly, risk assessments should take into account the consequences of 
imprecision on underestimation of risks [24]. For example, the benchmark dose level 
decreased by about 50% after adjustment for imprecise exposure data [24], and the exposure 
limits recommended by the U.S. EPA [25] and the World Health Organization (WHO) [26] 
would now probably need to be halved.
One more complication has been found to be of substantial importance for risk assessment. 
Methylmercury occurs as a common contaminant of seafood that, at the same time, contains 
essential nutrients [27]. The total impact of eating seafood therefore depends both on the 
contamination and the nutrient contents, and more nutritious seafood can appear to 
compensate for methylmercury toxicity [28]. At the same time, the benefits from otherwise 
healthy seafood are then diminished by the toxicant and can be exceeded by adverse effects 
at greater contamination levels. As the two factors operate in different directions, 
epidemiologists have dubbed this masking effect as negative (or reverse) confounding [29]. 
Clearly, we want our seafood to be safe and not to contain unwanted substances that 
diminish the beneficial effects, not to speak about adverse effects. Nonetheless, regulatory 
agencies usually aim only at securing a net benefit from seafood diets rather than optimizing 
the benefits by minimizing the risk of mercury toxicity.
Mercury compounds, in particular methylmercury, therefore serve as important reminders of 
complications (table 1) that can result in adverse effects being easily underestimated and 
thresholds overestimated. Some conclusions from international risk assessments illustrate 
this tendency. “The occurrence of prenatal intoxication also calls for caution,” was the 
scientific consensus in 1972, although this warning had no consequence at all [30]. Later on, 
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WHO experts also recognized that “clinical data from Japan indicate that the foetus is more 
sensitive than the mother,” but no special protection ensued [31]. Risk assessment for 
methylmercury continued to rely on average toxicity in adults and remained that way until 
2003 [26], when developmental toxicity was finally recognized, but the other considerations 
mentioned in table 1 remain to be addressed. Thus, even today, exposure limits for 
methylmercury are far less protective than officially claimed.
 The dose concept under uncertainty
Paracelsus’ poison dictum heralded the modern application of the NOAEL as a key concept 
in regulatory pharmacology. However, due to a variety of complexities (table 2), 
environmental toxicology has benefitted much less. While drugs must be tested for their 
efficacy and for adverse effects, most industrial chemicals have escaped such regulations. In 
the United States, the Toxic Substances Control Act, which dates back to the late 1970s, did 
not require testing of substances already in commerce at the time. It is even possible that the 
legislation discouraged chemical producers from testing substances that had already received 
blanket approval [32]. As a result, it is difficult today to judge whether or not a particular 
chemical is a “poison,” simply because of the lack of information on the dose-response 
relationship [32].
An additional problem is that industrial chemicals, especially those that are resistant to 
breakdown, can disseminate into the global environment and reappear in food chains far 
from the source. This was the case with the perfluorinated alkyl substances (PFASs) that 
were discovered in extremely high concentrations in the liver of remote polar bears and pilot 
whales [33]. The PFASs have been in use for over 60 years [34], the main uses being non-
stick kitchenware, raingear, impregnation of furniture textiles and carpets, other water- and 
stain-repellant uses, and additional uses, such as aqueous film-forming foams used for fire-
fighting purposes [34]. By about 2000, their global environmental dissemination became 
publicly known [35]. Today, virtually all Americans have detectable PFAS concentrations in 
their serum [36]. However, due to the multiple pathways, e.g., through consumer products, 
house dust, food chain contamination, and food packaging materials, the exposure sources 
are difficult to pinpoint, and the only known method to reduce the unwanted body burden is 
phlebotomy [37].
When foreign chemicals are unexpectedly detected in blood samples, the possible risks 
deserve to be ascertained, and that can be a protracted process. Thus, the U.S. Environmental 
Protection Agency issued a draft risk assessment for PFASs in 2005, but a final version has 
yet to appear, and the limits for drinking water issued in 2009 remain provisional [38].
Standardized animal testing may not necessarily reveal the effects that are thought to be 
critical in human beings, such as developmental neurotoxicity [39]. With the PFASs, early 
toxicology reports relied on spleen microscopy and general clinical chemistry to conclude 
that the immune system did not show any significant effects in non-human primates [40]. 
Later on, more sensitive methods applied in a rodent model showed deficient antibody 
responses to foreign proteins [41], even at serum concentrations that were fairly close to 
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those seen in exposed human populations. With time, adverse effects were found at lower 
and lower doses, as illustrated by the top curve in fig. 2.
While human data are crucial in order to evaluate the possible health risks, most evidence 
refers to cross-sectional data that are difficult to interpret, especially if the causative 
exposure may have happened sometime in the past [42], as suggested by the DOHaD 
concept [18]. When the hypothesis of immunotoxicity was tested in children’s response to 
childhood immunizations, the maternal pregnancy serum-PFAS concentration showed a 
strong negative correlation with the children’s vaccine antibody concentrations at age 5 
years, where a doubling in exposure was associated with an antibody loss of 40% or more 
[43]. A prospective study design involved blood collection from the pregnant mother and 
from the children 5 years later. These findings have been confirmed in one additional study 
[44], which, in addition, showed increased frequencies of common cold and gastroenteritis, 
but replications of such multi-year study designs complicate the desire to obtain 
confirmatory results within a reasonably short time frame.
The difficulty in obtaining crucial human evidence was recently highlighted by the Agency 
for Toxic Substances and Disease Registry (ATSDR), which stressed a number of 
uncertainties and then disregarded the recent reports on developmental PFAS exposures and 
their associations with adverse effects in children [45]. In regard to human immunotoxicity, 
we had calculated the so-called benchmark dose level [46], which is used by regulatory 
agencies as a basis for deriving safe levels of exposures [47, 48]. Our results suggested that 
current exposure limits [38, 45] may be more than 100-fold too high to protect against 
immunotoxicity in children. ATSDR disregarded this evidence, as our study did not include 
a “control group,” despite the fact that no such condition is warranted [47]. In the 
conclusions, the ATSDR draft instead focused on classical toxicity signs, such as changes in 
liver weight, in animal models [45].
The PFASs provide a clear and unfortunate example of the “untested-chemical assumption” 
that the lack of documentation means that no regulatory action is required [49]. In this case, 
the assumption ignored preliminary evidence on plausible effects and thus failed to inspire 
further exploration of possible risks. Clearly, the absence of replicated documentation from 
epidemiological studies should not be considered as a reason to conclude that adverse effects 
have not and will not occur [50]. I am sure that Paracelsus would have objected against 
chemicals not being considered poisons simply because no evidence of toxicity had been 
garnered. Thus, the PFASs reflect a failed scientific and regulatory approach to chemical 
safety [49]. The question is how toxicology should deal with this challenge in the future.
 The need for audacity in toxicology science
Scientific tradition demands solid evidence and replication before drawing conclusions, 
especially those that can have an impact on decisions in society. According to this 
conventional approach, about 20 years ago, a group of scientists reviewed the evidence on 
DOHaD-related toxicity and concluded: ”Differences in sensitivity between children and 
adults are chemical-specific and must be studied and evaluated on a case-by-case basis” 
[51]. Certainly, acetaminophen is less toxic to small children with an immature liver 
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metabolism, but does that really mean that all industrial chemicals must be tested for age-
dependent toxicity before providing children with additional protection?
Obtaining the necessary documentation can be difficult, especially when a study that fails to 
reach statistical significance is said to be “negative” or even misinterpreted as evidence that 
an association is absent [52]. As outlined above, toxicology research is always affected by 
uncertainties, each of which can easily blur a real association between a chemical hazard and 
its adverse effects. In particular, risks may be easily underestimated when exposure 
assessments are imprecise [23]. Uncertainty is often misunderstood to refer only to the risks, 
so that statistical acceptance of the null hypothesis is interpreted as proof of safety. In reality, 
uncertainty is not asymmetric and must also be viewed as an equal challenge to alleged 
safety. The latter aspect is illustrated by the lower curve in fig. 2. As better information 
becomes available, we are able to endorse the existence of safety at increasing levels of 
exposure – much in Paracelsus’ spirit. When perfect knowledge is available, we will also 
know exactly how much of a toxicant an individual can tolerate, although unfortunately, 
individual vulnerability may make it impossible to extrapolate this knowledge to the 
population level.
The demands for documentation and replication can impede preventive interventions, but 
they have also harmed research in a more general sense. When we identified the industrial 
chemicals covered by the major toxicology and public health journals in 2000–2009, the 
most frequently studied substances were mainly metals, mercury among them, each of 
which had resulted in hundreds of new articles every year in peer-reviewed journals [53]. 
This wealth of recent publications with a focus on well-studied compounds reflects a so-
called Matthew Effect [54], where the popularity among researchers and ongoing 
deliberations generate justification for continued research on the very same substances. 
Feasibility, funding, publication pace, and institutional agendas, are of course major 
determinants for academic research, along with the demands for replication, but all of these 
factors foster inflexibility and inertia, a vicious circle with a perpetual, positive feed-back 
that acts against the very purpose of toxicology.
As a further sign that science is not serving the changing needs of society in regard to 
potential chemical hazards, the environmental chemicals identified as a top research priority 
by the U.S. Environmental Protection Agency in 2006 [55] were barely covered by academic 
research up to 2009 [53], and not much since then. Accordingly, research on environmental 
chemicals primarily considers well-known problems, many of which still pose challenges, 
but little research focuses on the environmental problems of the future.
Part of the responsibility for demanding meticulous and repeated verification is due to 
industry interests [56] that may view new toxicology evidence as a financial threat. In my 
own case, when methylmercury from seafood emerged as a public health hazard, the tuna 
fishing industry set aside $25 million for a campaign to convince consumers that polluted 
tuna was safe [57]. This way, vested interests inject exaggerated or even manufactured 
uncertainties into the debate, sometimes through hidden sponsorships of alleged research 
studies [58].
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When public scares nonetheless happen, they are often considered ‘false positive’ events. 
Likewise, erroneous conclusions may occur in major medical journals [59], but such false 
positive findings seem to particularly affect certain fields, such as clinical research. On close 
examination of more than 80 alleged false positive cases relevant to public health, only a 
handful, such as the swine flu, were truly false negatives that resulted in wasted efforts, 
because the hazard did not materialize. Thus, costs due to overreactions are rare, while the 
costs due to false negatives can be truly excessive [60]. In regard to environmental 
chemicals, the majority has been poorly documented, if at all [61]. Ignoring the potential 
risks from poorly studied chemical hazards likely involves a very large number of potentially 
false negative conclusions. Some of these errors may in the end turn out to be extremely 
costly, as illustrated by asbestos, lead, mercury and many other hazards that were at first 
ignored [60, 62].
The so-called “untested-chemical assumption” therefore needs to be countered [49]. In fact, 
like climate change, a potential chemical hazard may still need to be taken seriously, even 
when a definite proof is not yet at hand. Thus, toxicology conclusions must always be based 
on a prudent interpretation of our current scientific knowledge, but they also need to take 
into account what could be realistically known by now, given the research studies completed 
so far.
Paracelsus’ motto was “Alterius non sit qui suus esse potest” which means “Do not try to be 
someone different, if you can be yourself.” Toxicology science needs audacity to stand by its 
values as a public health science and recognize that the modern complexities of chemical 
exposures require precaution and attention to the doses that can be tolerated without adverse 
effects (the lower curve in fig. 2) rather than a narrow focus solely on adverse effects (the 
upper curve).
 Conclusions
Developmental exposures, genetic predisposition and other sources of hypersusceptibility, 
multiple reasons for underestimated toxicity, and the continuous presence of uncertainty, put 
demands on toxicology that Paracelsus did not have to deal with. However, his example, 
with his stalwartness and unrelenting insistence on relying on facts rather than authority 
alone, with the purpose of protecting fellow human beings, should inspire toxicology to 
become an even more essential tool in public health and in dealing safely with industrial 
chemicals.
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Fig. 1. 
Paracelsus, at age 45, three years before he died in 1541 (contemporary copper engraving). 
Note Paracelsus’ motto on top.
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Fig. 2. 
With time, better knowledge allows appreciation that lower exposures must be ensured in 
order to avoid adverse health effects, and it is also realized that very small doses are 
tolerated without any risk of adverse effects. However, only with near-perfect knowledge 
will the two curves meet. It is the purpose of modern toxicology to responsibly interpret 
science so that adverse effects are avoided, although with due recognition that some low-
level exposures must be allowed. Redrawn from (63).
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Table 1
Complications in mercury toxicology that Paracelsus did not have to deal with.
• Different toxicity due to organomercury compounds
• Developmental susceptibility
• Genetic predisposition to toxic effects
• Underestimated toxicity due to exposure imprecision
• Negative confounding hiding the toxic effects
Basic Clin Pharmacol Toxicol. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Grandjean Page 15
Table 2
Modern challenges in toxicology where Paracelsus’ candor and obstinacy might be helpful.
• Most industrial chemicals have not been tested for toxicity
• Due to diffuse dissemination, exposures and their sources are complex
• Standard animal models may not be sensitive to critical effects in human beings
• Cross-sectional human data underestimate toxicity
• Prospective studies of exposed population are costly and time-consuming
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